期刊文献+

^(153)Sm-Annexin V凋亡显像的实验研究 被引量:1

Experimental studies on apoptosis imaging of ^(153)Sm-Annexin V
下载PDF
导出
摘要 目的:探讨放射性核素153Sm标记Annexin V凋亡显像的可行性。方法:采用环二乙三胺五醋酸(DTPA)法进行153Sm-Annexin V制备,并进行物理、化学及生物学检测。应用153Sm-Annexin V进行体外细胞培养及荷瘤小鼠动物凋亡显像实验。结果:经环DTPA法制备的153Sm-Annexin V无色透明,pH为7.4,比活度100μg/10 mCi/2 mL;放化纯RCP>90%,标记率为88.6%;无菌,无热原,LD50>333μg/kg体质量,血浆半衰期13 min;体外细胞培养及荷瘤小鼠动物凋亡显像实验均阳性。结论:153Sm-Annex in V作为放射性核素凋亡显像剂,标记率高,半衰期相对较长,利于进行连续追踪监测、捕捉细胞凋亡活动的高峰期,进而确立最佳凋亡显像时间窗,有广泛的临床应用前景。 Objective: This work aimed to investigate the feasibility of apoptosis imaging ofAnnexin V labeled with the radionuclide ^153Sm. Methods: ^153Sm-Annexin V was prepared by using the cyclic diethylene triamine pentaacetic acid (DTPA) method, after which physical, chemical, and biological assays of the protein were conducted. Apoptosis imaging experiment both for in vitro cell cul- ture and for tumor-bearing mice was performed using l'3Sm-Annexin V. Results: The features of 153Sm-Annexin V prepared via the cy- clic DTPA method are as follows: colorless and transparent, pH 7.4, radioactivity of 100 μg/10 mCi/2 mL, radiochemical purity of over 90%, and 88.6% radiolabeling rate. Annexin V is sterile, pyrogen-free, and presents an LD50 of 333 μg/kg body weight and plasma half-life of 13 min. Positive apoptosis images were obtained from both cultured cells and tumor-bearing mice. Conclusion: ^153Sm-An- nexin V, as a radionuclide-labeled apoptosis imaging agent, exhibits a high labeling rate and relatively long half-life. The agent can efficiently facilitate continuous tracking and capturing of apoptotic peak activity, thus establishing an optimal apoptosis imaging window period. These advantages indicate that the proposed imaging method has great potential in many clinical applications.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2013年第12期690-693,共4页 Chinese Journal of Clinical Oncology
关键词 凋亡显像 放射性核素显像 153钐 膜联蛋白V 恶性肿瘤 apoptosis imaging, radionuclide imaging, Samarium 153, Annexin V, malignant tumor
  • 相关文献

参考文献15

  • 1KerrJFR, Wyllie AH, Currie AR. Apoptosis:A Basic Biological Phenomenon With Wide--ranging Implications in Tissue Kinetics[J]. BrJ Cancer, 1972, 26:239-257.
  • 2Glaser M, GoggiJ, Smith G, et al. Improved radiosynthesis of the apoptosis marker 18F-ICMTll including biological evaluation[J]. Bioorg Med Chem Lett, 201 l, 21 (23):6945--6949.
  • 3Fortt R, Smith G, Awais RO, et al. Automated GMP synthesis of [(18)F]ICMT--11 for in vivo imaging of caspase-3 activity[J]. Nucl Med Biol, 2012, 39(7):1000-1005.
  • 4Shi H, Kwok RT, LiuJ, et al. Real-time monitoring of cell apopto- sis and drug screening using fluorescent fight-up probe with aggre- gation-induced emission characteristics[J]. J Am Chem Soc, 2012, 134(43):17972-17981.
  • 5Lederle W, Arns S, Rix A, et al. Failure of amaexin--based apopto- sis imaging in the assessment of anfiangiogenic therapy effects[J]. EJNMMI Res, 2011, 1(1):26.
  • 6Sobrio F, Medoc M, Martial L, et al. Automated Radiosynthesis of [(18)F]ML-10, a PET Radiotracer Dedicated to Apoptosis Imag- ing, on a TRACERLab FX-FN Module[J]. Mol Imaging Biol, 2013, 15(1):12-18.
  • 7Sun IC, Lee S, Koo H, et al. Caspase sensitive gold nanoparticle for apoptosis imaging in live cells[J]. Bioconjug Chem, 2010, 21(11): 1939-1942.
  • 8Vangestel C, Peeters M, Oltenfreiter R, et al. In vitro and in vivo evaluation of [^99mTc]-labeled tricarbonyl His-annexin A5 as an imaging agent for the detection of phosphatidylserine-expressing cells [J]. Nucl Med Biol, 2010, 37(8):965-975.
  • 9Vangestel C, Peeters M, Mees G, et al. In vivo imaging of apopto- sis in oncology: an update[J].Mol Imaging, 2011, 10(5):340-358.
  • 10Wang MW, Wang F, Zheng YJ, et al. An in vivo molecular imaging probe (18)F-Annexin B1 for apoptosis detection by PET/CT: preparation and preliminary evaluation[l]. Apoptosis, 2013, 18(2):238-247.

同被引文献33

  • 1Rubini G, Nicoletti A, Rubini D, et al. Radiometabolic treatment of bone-metastasizing cancer: from 186Rhenium to 223Radium[J]. Cancer Biother Radiopharm, 2014, 29: 1-11.
  • 2Fischer M, Kampen WU. Radionuclide therapy of bone metastases [J].Breast Care (Basel), 2012, 7:100-107.
  • 3Longo J, Lutz S, Johnstone C. Samarium -153 -ethylene diamine tetramethylene phosphonate, a beta -emitting bone -targeted radiopharmaceutical, useful for patients with osteoblastic bone metastases[J]. Cancer Manag Res, 2013,13:235-242.
  • 4Paes FM, Emani V, Hosein P, et al. Radiopharmaceuticals: when and how to use them to treat metastatic bone pain [J]. J Support Oncol, 2011,9:197-205.
  • 5Skora T; Kowalska T, Zawila K. Effectiveness of radioisotope therapy in bone metastases, based on personal experience[J]. Contemp Oncol (Pozn), 2012,16:201-205.
  • 6Gallicchio R, Giacomobono S, Nardelli A, et al. Palliative treatment of bone metastases with samarium-153 EOTMP at onset of pain[J]. J Bone Miner Metab, 2013,11. 00l:1O.1OO7/s00774-013-0507-0.
  • 7Storto G, Gallicchio R, Pellegrino T, et al. Impact of 1'F -fluoride PET -CT on implementing early treatment of painful bone metastases with Sm-153 EOTMP[J]. Nue! Med Bioi, 2013, 40:518-523.
  • 8Waldert M,Klatte T,Rernzi M,et al. Is 153Samarium-ethylene-diaminetetramethyl -phosphonate (EOTMP) bone uptake influenced by bisphosphonates in patients with castration-resistant prostate cancer [J]. World J Urol, 2012, 30:233-237.
  • 9Rasulova N, Lyubshin V, Arybzhanov 0, et al. Optimal timing of bisphosphonate administration in combination with samarium-153 oxabifore in the treatment of painful metastatic bone disease [J]. World J Nue! Med, 2013,12:14-18.
  • 10Lu J, Deng J, Zhao H, et al. Safety and feasibility of percutaneous vertebroplasty with radioactive (153)Sm PMMA in an animal model [J]. Eur J Radiol, 2011, 78:296-301.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部